Philadelphia Zantac Lawsuit Attorney

Prescription and over-the-counter Zantac have been found to cause cancer, and those who have been harmed due to taking this medication could be entitled to significant compensation. Zantac has been recalled, and the US Food and Drug Administration (FDA) has alerted healthcare providers and patients of these recalls and continues to conduct testing of these products. If you were affected by Zantac or believe you might be at risk after taking the prescription, contact our Philadelphia Zantac lawsuit attorneys from Ciccarelli Law Offices, we can handle your case and will fight for fair compensation, you can call us directly at (215) 228-0100.

Background on Zantac (Ranitidine)

Zantac is classified as an H2 antagonist used to treat various conditions such as heartburn, stomach ulcers, and gastroesophageal reflux disease (GERD). Millions of people throughout the United States regularly take both prescription and over-the-counter Zantac at the direction of their doctor to treat these conditions.

However, testing by an independent laboratory, and confirmed by the FDA, has discovered that Zantac and its active ingredient ranitidine metabolize into N-nitrosodimethylamine (NDMA).

NDMA has been classified by the World Health Organization (WHO) as a cancer-causing carcinogen since the 1970s. The FDA states that humans can intake a daily amount of 96 nanograms of NDMA each day safely, but that testing revealed that Zantac 150 mg tablets contained more than 2,500,000 nanograms of NDMA.

The FDA requested that all Zantac medications be removed from the market on April 1, 2020.

Cancers associated with Zantac

There are various types of cancer associated with Zantac, including the following:

• Prostate Cancer
• Liver Cancer
• Brain Cancer
• Bladder Cancer
• Lung Cancer (for non-smokers)
• Kidney (Renal) Cancer
• Testicular Cancer
• Intestinal Cancer
• Ovarian Cancer
• Stomach Cancer
• Throat/Nasal Cancer
• Esophageal Cancer
• Thyroid Cancer
• Colorectal Cancer
• Uterine Cancer
• Non-Hodgkin’s Lymphoma
• Pancreatic Cancer
• Acute Lymphoblastic Leukemia
• Breast Cancer

Criteria + Litigation Updates

To be eligible to join the lawsuits in these cases, a person must have:

• Used Zantac or a generic form of ranitidine
• Be younger than 64 if diagnosed with prostate cancer
• Have used the medication after October 1984
• Been diagnosed with these cancers between October 1985 and the present time
• Developed one or more of the injuries mentioned above within at least 12 months from the last use of the medication
• Use these medications for a minimum of one year
• Used Zantac or a generic once a week for a minimum of six months
• Been diagnosed with a qualifying injury within 20 years of the last dose of Zantac taken

A person is not considered eligible for these cases if you:

• They developed lung cancer and have been a smoker in the past 25 years
• Developed any of the injuries listed above as a result of a diagnosis prior to using Zantac
• Have lived in Michigan while taking Zantac or a generic
• Have developed an injury listed above as a result of a non-qualifying cancer
• Have developed an injury listed above as a result of any cancer prior to Zantac or generic usage
• Are currently being represented by an attorney

A multidistrict litigation location was determined in February to be West Palm Beach, Florida, under Judge Rosenberg. As of January 2020, there have been 137 cases filed in federal court concerning Zantac or generic ranitidine injuries. There are pending epidemiology reports that could be favorable to plaintiffs in this case.

Schedule a Free Case Evaluation | (215) 228-0100

If you or somebody you care about has been diagnosed with one of the qualifying cancers or injuries listed above after taking Zantac or generic ranitidine, contact the Philadelphia injury lawyers at Ciccarelli Law Offices. Our Zantac attorneys in Philadelphia have extensive experience handling these cases, and we are ready to help clients throughout this area. You can contact us for a free consultation of your case by clicking here to calling (215) 228-0100.